Package Leaflet: Information for the User
Actocortina 373 mg Powder for Solution for Injection
Hydrocortisone
Read all of this leaflet carefully before you start using this medicine, because it contains important information for you., as it contains important information for you.
|
Contents of the Package Leaflet
5 Storage of Actocortina
Actocortina belongs to a group of hormonal preparations called systemic corticosteroids, which act as potent anti-inflammatory agents.
Actocortina is used for the treatment of:
tenosynovitis and bursitis
Do not use Actocortina
Except in emergency situations, this medicine should not be used in the following cases, as there is a risk of worsening. This decision should be made by your doctor:
Warnings and precautions
Consult your doctor or pharmacist before starting treatment with Actocortina.
You should inform your doctor if you have or have had any of the following disorders:
Contact your doctor if you experience blurred vision or other visual disturbances.
Rapid intravenous injection of high doses of Actocortina can sometimes cause acute cardiac problems, so injections should be administered slowly or by infusion.
This medicine increases the risk of infection and increases the severity of infections. It is recommended to rule out infections such as chickenpox or measles before starting treatment. It can also increase the risk of eye infections.
Live vaccines should not be administered to patients being treated with corticosteroids, and the response to other types of vaccines may be diminished.
Long-term systemic therapy with Actocortina can cause adrenal insufficiency, Cushing's syndrome, or unbalanced blood sugar levels in your body.
Actocortina can cause mental disorders, including euphoria, insomnia, mood changes, personality changes, depression, and psychotic tendencies. This can occur during the start of treatment and during dose adjustments. The risks may be greater when high doses are administered. Most reactions resolve after dose reduction.
Treatment with high doses of Actocortina can cause benign "steroid diabetes". This is reversible when therapy is stopped. In diabetics, treatment usually causes dysregulation, which can be compensated by adjusting the insulin dose.
Contact your doctor immediately if you experience muscle weakness, muscle pain, cramps, and stiffness while using hydrocortisone. They may be symptoms of a condition called thyrotoxic periodic paralysis, which can occur in patients with hyperactivity of the thyroid gland (hyperthyroidism) treated with hydrocortisone. You may need additional treatment to alleviate this condition.
Children and Adolescents
It can cause growth retardation in childhood and adolescence, which may be irreversible.
In premature infants, it can cause hypertrophic cardiomyopathy. If hydrocortisone is administered to a premature newborn, it may be necessary to monitor heart function and structure.
Elderly Patients
This medicine can have greater consequences in these patients, such as osteoporosis, hypertension, hypokalemia, diabetes, increased risk of infections, and skin thinning. Close medical supervision is required to avoid life-threatening reactions.
Other Medicines and Actocortina
Tell your doctor if you are taking, have recently taken, or might take any other medicines.
The following medicines reduce the therapeutic effect of Actocortina:
The following medicines can increase the therapeutic effect of Actocortina:
Actocortina reduces the effects of the following medicines:
Actocortina can increase the effects of the following medicines:
Other interactions with medicines
Actocortina can interact with other medicines, so your doctor will perform thorough checks if you are taking these medicines.
Actocortina increases the toxicity of digitalis glycosides (e.g. digoxin) and the risk of gastrointestinal bleeding and ulceration with concomitant use of medicines such as aspirin and non-steroidal anti-inflammatory drugs (NSAIDs).
Concomitant use of Actocortina with fluoroquinolones (drugs used to treat bacterial infections) can increase the risk of tendon rupture.
Corticosteroids can reduce the effects of certain types of vaccines.
Using Actocortina with Food
Licorice can increase the risk of side effects of Actocortina.
Pregnancy, Breast-feeding, and Fertility
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.
Pregnancy
Actocortina should not be used during pregnancy, nor in women of childbearing age who are not using contraceptive methods.
Breast-feeding
Actocortina is excreted in breast milk. A risk to the newborn or breast-fed child cannot be excluded.
Your doctor will decide whether you should stop breast-feeding or stop the treatment.
Driving and Using Machines
No studies on the effects on the ability to drive and use machines have been performed.
Drug Analysis/Anti-Doping Control
Athletes are informed that this medicine contains a component that can result in a positive doping control test.
Actocortina contains Sodium
This medicine contains 47.29 mg of sodium (main component of cooking/table salt) per vial. This is equivalent to 2.4% of the maximum recommended daily intake of sodium for an adult.
Your doctor will decide on the injection site, the amount of medicine, and the number of injections to be administered, depending on the disease to be treated and its severity. Your doctor will administer the lowest effective dose for the shortest duration necessary to relieve symptoms.
Your doctor or another healthcare professional will administer the treatment. The vial contents should be dissolved with injection water and administered by intramuscular, slow intravenous, drop-by-drop, or continuous infusion injection.
The recommended dose is as follows:
Adults
Generally, the recommended single dose range, although not limited, varies from a fraction of the vial contents (less than 74.53 mg of hydrocortisone) to approximately 372.65 mg of hydrocortisone administered by slow intravenous injection over a period of 1 to 10 minutes (for doses of 372.65 mg or higher). This dose may be repeated at intervals of 2, 4, or 6 hours, depending on the disease being treated and the patient's response. Alternatively, this medicine can be administered as an intravenous infusion. A clinical effect is observed within 2 to 4 hours and persists for up to 8 hours after intravenous injection. The same dose can be administered by intramuscular injection, but the response is likely to be slower, especially in shock. The maximum dose should not exceed 6 g/day.
Use in Children
Although the dose of Actocortina can be reduced for infants and children, it is governed more by the severity of the condition and the response than by age or body weight, but should not be less than 25 mg per day.
Elderly Patients
If you use Actocortina for a prolonged period, you will have an increased risk of diabetes, hypertension, congestive heart failure, osteoporosis, and depression.
Close clinical supervision is required to avoid life-threatening reactions.
Patient with Renal Impairment
If you have severe kidney problems, your doctor may monitor you and may need to adjust the dose.
Patient with Hepatic Impairment
You are more likely to experience serious side effects. Dose adjustments may be necessary.
If you use more Actocortina than you should
In prolonged treatments, an increase in cortisol levels in the blood may occur, which subsides within a few days after stopping the medication.
No cases of overdose have been reported. In case of overdose or accidental ingestion, consult your doctor and/or hospital.
If you forget to use Actocortina
Do not take a double dose to make up for forgotten doses.
If you stop using Actocortina
Your doctor will indicate the duration of your treatment with Actocortina.
Treatment should not be stopped abruptly. Your doctor will indicate how to do it, as rapid withdrawal of Actocortina after prolonged treatment can lead to important complications such as acute adrenal insufficiency, hypotension, hormonal disturbances, or death.
A "withdrawal syndrome" may also occur, including fever, myalgia, arthralgia, rhinitis, conjunctivitis, painful/pruritic skin nodules, and weight loss.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
The adverse effects of Actocortina depend on the dose, the time of administration, and the duration of treatment. Adverse reactions can be minimized by using the lowest effective dose for the shortest possible time.
The following adverse drug reactions have been reported with hydrocortisone administered at high doses or for indications other than replacement therapy in adrenal insufficiency, although the frequency is unknown.
Organs/Systems | Frequency | Adverse Effect |
Infections and Infestations | Unknown | increased risk of infections, candida fungal infection, worsening of eye infections |
Blood and Lymphatic System Disorders | Unknown | increased white blood cell count |
Immune System Disorders | Unknown | allergic reactions |
Endocrine Disorders | Unknown | withdrawal syndrome (headache, nausea, dizziness, decreased appetite, weakness, mood changes, altered level of consciousness, and inappropriate responses to stress situations), growth retardation in children, Cushing's syndrome mainly characterized by a change in fat distribution (moon face, central obesity, buffalo hump), thyroid disorder, manifestation of latent hyperparathyroidism |
Metabolic and Nutrition Disorders | Unknown | increased appetite, decreased potassium and sodium levels, increased ketone bodies in blood, hyperglycemic hyperosmolar state, tumor lysis syndrome, altered acid-base balance in the body |
Psychiatric Disorders | Unknown | euphoria, depression, corticosteroid-induced psychotic disorder, insomnia, mood changes, personality changes, mania |
Nervous System Disorders | Unknown | fat deposition around the spinal cord, increased intracranial pressure in children with papilledema (more frequent when withdrawing the medication), worsening of epilepsy, after intravenous administration, a tingling sensation may appear in some areas of the body that usually disappears within a few minutes |
Eye Disorders | Unknown | cataract, glaucoma, papilledema, posterior subcapsular cataracts, narrowing of the cornea or sclera, central serous chorioretinopathy, blurred vision |
Cardiac Disorders | Unknown | worsening of congestive heart failure, myocardial disorder, arrhythmia, thickening of the heart muscle (hypertrophic cardiomyopathy) in premature newborns |
Vascular Disorders | Unknown | thromboembolism, hypertension, thrombosis |
Gastrointestinal Disorders | Unknown | feeling of heaviness after meals, gastric or duodenal ulcer, pancreatitis, gastritis, pain in the upper abdomen, abdominal discomfort, nausea |
Skin and Subcutaneous Tissue Disorders | Unknown | skin atrophy, bruising, increased hair growth, stretch marks, acne, dermatitis, increased sweating, peeling in an extensive area of the skin greater than 30% of the body surface (toxic epidermal necrolysis), widespread rash with blisters and skin peeling that occurs especially around the mouth, nose, eyes, and genitals (Stevens-Johnson syndrome), redness and itching |
Musculoskeletal and Connective Tissue Disorders | Unknown | osteoporosis, bone fractures, muscle disorders, bone death, tendon rupture and inflammation |
Renal and Urinary Disorders | Unknown | need to urinate at night, kidney stones |
Reproductive System and Breast Disorders | Unknown | menstrual irregularities, including absence |
General Disorders and Administration Site Conditions | Unknown | healing alterations |
Investigations | Unknown | weight gain, decreased blood cell count (eosinophils and lymphocytes), increased blood cell count (platelets), elevated cholesterol in blood, elevated triglycerides in blood, increased lipoproteins, increased ocular pressure, alterations in diabetes control |
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the label and carton. The expiration date is the last day of the month indicated.
Store below 25°C. Store in the original packaging to protect it from light.
Once the solution is reconstituted, it should be stored in the refrigerator (between 2°C and 8°C) and cannot be used after 24 hours from reconstitution.
Medicines should not be thrown away through wastewater or household waste. Deposit the containers and medicines you no longer need at the SIGRE Point of the pharmacy. In case of doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. This way, you will help protect the environment.
Composition of Actocortina
The active ingredient is sodium hydrocortisone phosphate. Each vial contains 372.65 mg of hydrocortisone (equivalent to 500 mg of sodium hydrocortisone phosphate).
Appearance of Actocortina and Package Contents
White to bone-colored powder. The sterile powder is packaged in a 10 ml type I colorless glass vial.
Each package contains 10 vials
Marketing Authorization Holder
CHEPLAPHARM Arzneimittel GmbH
Ziegelhof 24
17489 Greifswald
Germany
Manufacturer
B.BRAUN MEDICAL, S.A.
Ronda de los Olivares
Polígono Industrial Los Olivares
Parcela 11. 23009; Jaén
Spain
Local Representative
Laboratorios Rubió, S.A.
Industria, 29 - Pol. Ind. Comte de Sert
08755 Castellbisbal (Barcelona)
Spain
Date of Last Revision of this Prospectus:August 2025
Other Sources of Information
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es
------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Dissolve the contents of the vial with water for injection and administer by intramuscular injection, slow intravenous injection, drop by drop, or continuous infusion:
In the absence of compatibility studies, this medicine should not be mixed with others.